2026 Q3 - tulosraportti
UUTTA
1 päivä sitten
‧21 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 19 | ||
| 7 390 | ||
| 1 406 | ||
| 6 697 | ||
| 23 407 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.3.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 12.11. | ||
2026 Q2 - tulosraportti 19.8. | ||
2026 Q1 - tulosraportti 15.5. | ||
2025 Q4 - tulosraportti 3.3. | ||
2025 Q3 - tulosraportti 12.11.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- 4 t sittenLifecare: Look at the actual progress, not just DNB Carnegie's negative headline. I find it interesting how DNB Carnegie chooses to emphasise the lack of a regulatory timeline while giving much less attention to the operational progress Lifecare has actually achieved. Let's look at the facts. On September twenty-ninth, Lifecare confirmed that it had successfully manufactured its first functional glucose-monitoring implants in Bergen. By October twenty-sixth, the company reported nineteen implants successfully completing qualification testing across successive production runs in less than one month. The company has also acquired Ocean TuniCell, gaining laboratory infrastructure, cleanroom facilities, specialised equipment and technical expertise. And according to yesterday's quarterly report, the operating loss has fallen from approximately sixty-six million kroner in the third quarter of twenty twenty-five to approximately twelve million kroner in the third quarter of twenty twenty-six. These are real operational developments, not promises. Yes, controlled and fully reproducible manufacturing still needs to be established. Yes, the clinical application has not yet been submitted. Nobody should pretend otherwise. But there is a significant difference between a company making no progress and a company making measurable progress while completing the remaining technical and regulatory requirements. DNB Carnegie is entitled to its assessment. Investors are equally entitled to question whether its negative emphasis adequately reflects the progress being made. It is also worth remembering that this is commissioned research, not an objective verdict on Lifecare's future. My point is simple: Don't confuse an analyst's opinion with the underlying facts. A negative report does not erase successful production batches, improved infrastructure or substantially reduced operating losses. Every investor must make their own decisions, but those decisions deserve to be based on the complete picture rather than fear or a single pessimistic headline. Read the company's official announcements. Evaluate the risks. Think independently. Sources: Lifecare, September twenty-ninth: https://lifecare.no/mfn_news/lifecare-successfully-manufactures-first-functional-implants-in-house-in-bergen/ Lifecare, October twenty-sixth: https://lifecare.no/mfn_news/lifecare-advances-rapidly-towards-repeatable-in-house-implant-manufacturing-at-new-bergen-facilities/ Lifecare quarterly results, November twelfth: https://mfn.se/a/lifecare/life-lifecare-asa-q3-2026-resultsIt might be an idea to go back a bit further in an analysis than some news in the last month. Why produce something no one can buy? The market does not exist until you have approval. Yes, it is some veterinary stuff, but no progress is mentioned on that either.
- ·17 t sittenThe DnB Carnegie report arrived too. Not very pleasant reading for anyone who thinks this one is heading to the moon. I recommend everyone to read it though.Hardly believe that. Little doubt that this one is going to the moon, or to the grave... ETA? Not terribly long until. Just take a stake, if the right announcement comes you won't get in at range 0.2-0.5... Here you lose your money, or join a Circio 😉
- ·20 t sittenThey only have 30 million left in the account before it is empty - and they haven't even started with clinical trials. It would be foolish to wait until the cash register is completely empty before they raise money...
- ·21 t sittenThis was pretty much as good as one could expect at this stage. Low costs and the production lines are finding their form. It will be a few quarters before anything major happens and the stock is at its cheapest. The gambling lies in the approval, and there is a pretty good probability that it could come?The difference now from before is that they applied for approval last year, this year the application is not even present and no plan for when they will apply... Must be the veterinary market one goes for then....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
UUTTA
1 päivä sitten
‧21 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- 4 t sittenLifecare: Look at the actual progress, not just DNB Carnegie's negative headline. I find it interesting how DNB Carnegie chooses to emphasise the lack of a regulatory timeline while giving much less attention to the operational progress Lifecare has actually achieved. Let's look at the facts. On September twenty-ninth, Lifecare confirmed that it had successfully manufactured its first functional glucose-monitoring implants in Bergen. By October twenty-sixth, the company reported nineteen implants successfully completing qualification testing across successive production runs in less than one month. The company has also acquired Ocean TuniCell, gaining laboratory infrastructure, cleanroom facilities, specialised equipment and technical expertise. And according to yesterday's quarterly report, the operating loss has fallen from approximately sixty-six million kroner in the third quarter of twenty twenty-five to approximately twelve million kroner in the third quarter of twenty twenty-six. These are real operational developments, not promises. Yes, controlled and fully reproducible manufacturing still needs to be established. Yes, the clinical application has not yet been submitted. Nobody should pretend otherwise. But there is a significant difference between a company making no progress and a company making measurable progress while completing the remaining technical and regulatory requirements. DNB Carnegie is entitled to its assessment. Investors are equally entitled to question whether its negative emphasis adequately reflects the progress being made. It is also worth remembering that this is commissioned research, not an objective verdict on Lifecare's future. My point is simple: Don't confuse an analyst's opinion with the underlying facts. A negative report does not erase successful production batches, improved infrastructure or substantially reduced operating losses. Every investor must make their own decisions, but those decisions deserve to be based on the complete picture rather than fear or a single pessimistic headline. Read the company's official announcements. Evaluate the risks. Think independently. Sources: Lifecare, September twenty-ninth: https://lifecare.no/mfn_news/lifecare-successfully-manufactures-first-functional-implants-in-house-in-bergen/ Lifecare, October twenty-sixth: https://lifecare.no/mfn_news/lifecare-advances-rapidly-towards-repeatable-in-house-implant-manufacturing-at-new-bergen-facilities/ Lifecare quarterly results, November twelfth: https://mfn.se/a/lifecare/life-lifecare-asa-q3-2026-resultsIt might be an idea to go back a bit further in an analysis than some news in the last month. Why produce something no one can buy? The market does not exist until you have approval. Yes, it is some veterinary stuff, but no progress is mentioned on that either.
- ·17 t sittenThe DnB Carnegie report arrived too. Not very pleasant reading for anyone who thinks this one is heading to the moon. I recommend everyone to read it though.Hardly believe that. Little doubt that this one is going to the moon, or to the grave... ETA? Not terribly long until. Just take a stake, if the right announcement comes you won't get in at range 0.2-0.5... Here you lose your money, or join a Circio 😉
- ·20 t sittenThey only have 30 million left in the account before it is empty - and they haven't even started with clinical trials. It would be foolish to wait until the cash register is completely empty before they raise money...
- ·21 t sittenThis was pretty much as good as one could expect at this stage. Low costs and the production lines are finding their form. It will be a few quarters before anything major happens and the stock is at its cheapest. The gambling lies in the approval, and there is a pretty good probability that it could come?The difference now from before is that they applied for approval last year, this year the application is not even present and no plan for when they will apply... Must be the veterinary market one goes for then....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 19 | ||
| 7 390 | ||
| 1 406 | ||
| 6 697 | ||
| 23 407 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.3.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 12.11. | ||
2026 Q2 - tulosraportti 19.8. | ||
2026 Q1 - tulosraportti 15.5. | ||
2025 Q4 - tulosraportti 3.3. | ||
2025 Q3 - tulosraportti 12.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
UUTTA
1 päivä sitten
‧21 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.3.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 12.11. | ||
2026 Q2 - tulosraportti 19.8. | ||
2026 Q1 - tulosraportti 15.5. | ||
2025 Q4 - tulosraportti 3.3. | ||
2025 Q3 - tulosraportti 12.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- 4 t sittenLifecare: Look at the actual progress, not just DNB Carnegie's negative headline. I find it interesting how DNB Carnegie chooses to emphasise the lack of a regulatory timeline while giving much less attention to the operational progress Lifecare has actually achieved. Let's look at the facts. On September twenty-ninth, Lifecare confirmed that it had successfully manufactured its first functional glucose-monitoring implants in Bergen. By October twenty-sixth, the company reported nineteen implants successfully completing qualification testing across successive production runs in less than one month. The company has also acquired Ocean TuniCell, gaining laboratory infrastructure, cleanroom facilities, specialised equipment and technical expertise. And according to yesterday's quarterly report, the operating loss has fallen from approximately sixty-six million kroner in the third quarter of twenty twenty-five to approximately twelve million kroner in the third quarter of twenty twenty-six. These are real operational developments, not promises. Yes, controlled and fully reproducible manufacturing still needs to be established. Yes, the clinical application has not yet been submitted. Nobody should pretend otherwise. But there is a significant difference between a company making no progress and a company making measurable progress while completing the remaining technical and regulatory requirements. DNB Carnegie is entitled to its assessment. Investors are equally entitled to question whether its negative emphasis adequately reflects the progress being made. It is also worth remembering that this is commissioned research, not an objective verdict on Lifecare's future. My point is simple: Don't confuse an analyst's opinion with the underlying facts. A negative report does not erase successful production batches, improved infrastructure or substantially reduced operating losses. Every investor must make their own decisions, but those decisions deserve to be based on the complete picture rather than fear or a single pessimistic headline. Read the company's official announcements. Evaluate the risks. Think independently. Sources: Lifecare, September twenty-ninth: https://lifecare.no/mfn_news/lifecare-successfully-manufactures-first-functional-implants-in-house-in-bergen/ Lifecare, October twenty-sixth: https://lifecare.no/mfn_news/lifecare-advances-rapidly-towards-repeatable-in-house-implant-manufacturing-at-new-bergen-facilities/ Lifecare quarterly results, November twelfth: https://mfn.se/a/lifecare/life-lifecare-asa-q3-2026-resultsIt might be an idea to go back a bit further in an analysis than some news in the last month. Why produce something no one can buy? The market does not exist until you have approval. Yes, it is some veterinary stuff, but no progress is mentioned on that either.
- ·17 t sittenThe DnB Carnegie report arrived too. Not very pleasant reading for anyone who thinks this one is heading to the moon. I recommend everyone to read it though.Hardly believe that. Little doubt that this one is going to the moon, or to the grave... ETA? Not terribly long until. Just take a stake, if the right announcement comes you won't get in at range 0.2-0.5... Here you lose your money, or join a Circio 😉
- ·20 t sittenThey only have 30 million left in the account before it is empty - and they haven't even started with clinical trials. It would be foolish to wait until the cash register is completely empty before they raise money...
- ·21 t sittenThis was pretty much as good as one could expect at this stage. Low costs and the production lines are finding their form. It will be a few quarters before anything major happens and the stock is at its cheapest. The gambling lies in the approval, and there is a pretty good probability that it could come?The difference now from before is that they applied for approval last year, this year the application is not even present and no plan for when they will apply... Must be the veterinary market one goes for then....
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 19 | ||
| 7 390 | ||
| 1 406 | ||
| 6 697 | ||
| 23 407 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt






